Quick Answer
Contineum Therapeutics, Inc. reported Diluted EPS of $2.17 per share (loss) for fiscal year 2025.
Contineum Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.17 | +0.5% |
| 2024 | -$2.18 | -2825.0% |
| 2023 | $0.08 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | -$0.40 | +85.1% | -2.6% |
| June 30, 2024 | -$0.39 | -146.4% | +85.5% |
| September 30, 2023 | -$2.69 | — | -420.2% |
| June 30, 2023 | $0.84 | — | — |
- Contineum Therapeutics, Inc. showed an increase of +0.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Contineum Therapeutics, Inc.’s diluted eps has declined by 2812.5% (from $0.08 per share to $2.17 per share (loss)).
- The most recent figure is from Contineum Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: